MDGL
Madrigal Pharmaceuticals Inc
522.00$
-1.8%
vs. previous close
Closing price · As of: Sep 21, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -32.3% | -39.6% | +366.7% | +152.4% | -8.9% | -35.1% | -4.8% | +32.6% | +76.7% | +62.7% | +20.9% | |
| – | -99.6% | +11,233.7% | +366.0% | +152.7% | -9.3% | -35.2% | -4.7% | +33.0% | +76.4% | +62.1% | +20.6% | |
| – | -24.0% | +15.8% | +267.0% | -61.4% | -18.6% | +15.6% | -32.8% | +814.1% | -69.9% | +0.1% | +98.7% | |
| – | -31.9% | -39.2% | +372.9% | +152.6% | -9.2% | -35.3% | -4.9% | +32.7% | +76.7% | +46.1% | +6.2% | |
| – | -84.1% | – | – | – | – | – | – | – | – | – | +149.9% | |
| – | – | – | – | – | – | – | – | – | – | – | +119.7% | |
| – | – | -99.3% | +10,117.2% | -24.6% | +421.6% | -11.6% | +57.4% | -63.5% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | +56.1% | |
| – | -49.9% | -73.0% | +109.5% | -16.0% | +201.9% | +84.5% | +64.2% | +113.9% | +42.4% | +22.4% | +128.2% | |
| – | +59.5% | -90.3% | +109.5% | -16.0% | +197.6% | +85.3% | +65.0% | +50.8% | +2.3% | +42.8% | +83.3% | |
| – | +430.4% | – | – | – | – | +1.0% | +28.9% | +46.8% | -12.5% | +86.5% | +3.6% | |
| – | -96.7% | +644.9% | +153.1% | +28.9% | -52.6% | -13.7% | +2,002.3% | +11.5% | +17.7% | +55.5% | +12.1% | |
| – | -100.0% | – | – | – | – | – | – | – | +134.3% | +1.8% | +189.1% | |
| – | -22.6% | -27.8% | +400.6% | +161.7% | -12.7% | -42.4% | -18.3% | +0.7% | +105.3% | +86.1% | -20.1% | |
| – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -93.9% | +2,943.6% | +135.3% | +20.8% | +4.0% | +0.3% | +7.0% | +3.6% | +9.0% | +13.8% | +5.5% |
Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.